Tinsley

Tinsley Therapeutics is a pre-clinical stage biotechnology company dedicated to developing first-in-class small molecule therapies for the treatment of aggressive solid tumors. The company's research centers on the Sigma-2 receptor (TMEM97), a protein that is highly overexpressed in various cancer types and plays a critical role in regulating cell survival and cholesterol homeostasis. By developing potent and selective Sigma-2 ligands, Tinsley aims to trigger tumor-specific cell death and overcome resistance to conventional therapies. Their lead programs are currently focused on high-unmet-need oncology indications, including pancreatic cancer.